Figure 11.
In vivo cytotoxicity. To investigate the in vivo toxicity of the therapeutics, levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and creatine kinase muscle brain fraction (CK-MB) enzymes were quantified in serum samples of mice infected and treated, 1 and 15 days post-therapy. Samples of naive (non-infected and non-treated) mice were used as control. Bars represent the mean ± standard deviation of the groups. (*) indicates a significant difference as compared to the saline and B/Mic groups (p < 0.05). (**) indicates a statistically significant difference as compared to the miltefosine group (p < 0.05). (***) indicates a statistically significant difference as compared to the b-AD group (p < 0.05). (#) indicates a statistically significant difference as compared to the miltefosine, b-AD and b-AD/Mic groups (p < 0.05).
